🇺🇸 FDA
Patent

US 10364238

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

granted A61KA61K31/4439A61K31/445

Quick answer

US patent 10364238 (N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors) held by KalVista Pharmaceuticals Limited expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
KalVista Pharmaceuticals Limited
Grant date
Tue Jul 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/4439, A61K31/445, A61K31/496, A61P